Cargando…
Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer
Capture-based next-generation sequencing (NGS) is a potentially useful diagnostic method to measure tumor tissue DNA in blood as it can identify concordant mutations between cell-free DNA (cfDNA) and primary tumor DNA in lung cancer patients. In this study, the sensitivity, specificity and accuracy...
Autores principales: | Cui, Shaohua, Zhang, Wei, Xiong, Liwen, Pan, Feng, Niu, Yanjie, Chu, Tianqing, Wang, Huimin, Zhao, Yizhuo, Jiang, Liyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356840/ https://www.ncbi.nlm.nih.gov/pubmed/27926526 http://dx.doi.org/10.18632/oncotarget.13741 |
Ejemplares similares
-
Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016) -
Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations
por: Liu, Jun, et al.
Publicado: (2018) -
Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017) -
ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
por: Dacic, Sanja, et al.
Publicado: (2016) -
Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)